NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
Clinical Trials
3 trialsNCT03052608 2025-11-25
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
Phase 3 Active not recruiting
NCT06858410 2025-03-05
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Guangdong Association of Clinical Trials
Phase 3 Not yet recruiting